Kihara James 4

What Happened
Kihara James, Principal Accounting Officer of ACADIA Pharmaceuticals (ACAD), sold 5,401 shares of ACAD common stock in an open-market transaction on May 26, 2026. The weighted-average price reported was $21.18 per share, for proceeds of approximately $114,393. This filing reports a sale (S), which is typically a disposition rather than a direct bullish signal.

Key Details

• Transaction date: 2026-05-26; filing date: 2026-05-27 (timely filed the next day).
• Shares sold: 5,401; weighted-average price: $21.18; total proceeds: ~$114,393.
• Price range: per footnote, trades occurred at prices between $21.1801 and $21.185; the filer can provide a breakdown of quantities at each price on request.
• Shares owned after the transaction: not specified in the summary provided; the filing notes that holdings include 781 shares acquired May 15, 2026 under an employee stock purchase plan (ESPP).
• Transaction code: S = Sale. No 10b5‑1 plan or other trading plan is indicated in the disclosed items.

Context
Sales by company officers can be routine (e.g., diversification, tax withholding, or payroll-related sales) and do not by themselves indicate the insider’s view of the company’s prospects. Purchases tend to be viewed as more informative. For full details, including any post-transaction holdings or additional remarks, consult the full Form 4 filing (Accession #0001816160-26-000008).